Register now to learn about a new option for relapsed or refractory follicular lymphoma

General Discussions

FDA Grants Priority Review to Belantamab Mafodotin for Relapsed/Refractory Myeloma

By Kristie L. Kahl
General Discussions - Discussions
25 replies
The FDA granted a priority review to belantamab mafodotin for the treatment of heavily pre-treated patients with relapsed or refractory multiple myeloma, according to GlaxoSmithKline.1

With this, belantamab mafodotin has potential to be the first anti-BCMA treatment available to patients.

The company based is biologics license application on data from the pivotal, open-label, two-arm, phase 2 DREAMM-2 (DRiving Excellence in Approaches to Multiple Myeloma) study – designed to evaluate belantamab mafodotin in 293 patients with relapsed or refractory multiple myeloma with disease progression after 3 or more lines of therapy and who were refractory to immunomodulatory drugs and proteasome inhibitors, and refractory or intolerant (or both) to an anti-CD38 monoclonal antibody.2

Patients demonstrated an overall response rate of 31% (97.5% CI, 20.8–42.6), with 30 of 97 patients experiencing a response to therapy. Of these responders, 18 achieved a very good partial response or better, including three patients with stringent complete or complete responses.

The median duration of response and overall survival have not been reached at 6 months of follow-up.

No new safety signals were seen. The safety and tolerability profile was consistent with previously reported data on belantamab mafodotin, with the 3 most commonly reported grade 3 or 4 edverse events including keratopathy (27%), thrombocytopenia (20%), and anemia (20%).

“Each day in my practice, I see patients who would benefit from additional therapeutic options because their disease has advanced and is no longer responding to available treatments,” principal investigator of the study, Sagar Lonial, MD, who is also chief medical officer at Winship Cancer Institute of Emory University and chair of the Emory Department of Hematology and Medical Oncology, said in a press release.3

“In recent years, (B-cell maturation antigen [BCMA]) has become one of the most promising targets in multiple myeloma research,” he added. “The data…from DREAMM-2 not only reinforce the significance of BCMA as a potentially viable target, but also underscore the potential of belantamab mafodotin, if approved, as a practical treatment option in this patient population.”

References:
1. GlaxoSmithKline. US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma. Available from: https://www.prnewswire.com/news-releases/us-food-and-drug-administration-fda-grants-priority-review-of-belantamab-mafodotin-for-patients-with-relapsed-or-refractory-multiple-myeloma-300990248.html?tc=eml_cleartime. Accessed on January 21, 2020.
2. Lonial S, Lee HC, Badros A. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. doi:10.1016/S1470-2045(19)30788-0.
3. GlaxoSmithKline. Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma. Available from: https://www.gsk.com/en-gb/media/press-releases/pivotal-dreamm-2-study-demonstrated-a-clinically-meaningful-overall-response-rate-with-belantamab-mafodotin-gsk2857916-for-patients-with-relapsedrefractory-multiple-myeloma. Accessed on: January 21, 2020.
 
By shawn
Jan 25, 2020 4:34:15 am
I really enjoyed reading your article. I found this as an informative and interesting post, so i think it is very useful write my dissertation for me and knowledgeable. I would like to thank you for the effort you made in writing this article.
By ariachris56
Jan 28, 2020 1:44:53 am
thanks for this post
By Andy
Jan 28, 2020 6:42:55 am
Useful reading this post. Keep sharing! Ford SWOT analysis
By ZackENG
Feb 06, 2020 8:57:40 am
Thanks, very informative post! By the way, I used this writing service to get cheap essay help and other paper help. They sometimes got such articles as here, too.
By soul
Feb 06, 2020 11:05:28 pm
"Of these responders, 18 achieved a very good partial response or better, including three patients with stringent complete or complete responses." Free clicker heroes online
By samuelddarden
Feb 18, 2020 10:20:02 pm
An obligation of appreciation is all together to share it. I have been playing this monster legends wiki for couple of years now and i am still not bored. You should try it!
By phamyen
Feb 24, 2020 10:10:48 pm
I found this as an informative and interesting post, so i think it is very useful write my dissertation for me and knowledgeable. I would like to thank you for the effort you made in writing this article Free vidmate online.
By jakethomas
Mar 06, 2020 5:32:20 am
Of these responders, 18 achieved a very good partial response or better, including three here patients with stringent complete or complete responses.
By marySellena
Mar 19, 2020 12:46:02 am
I think the priority evaluation has been a great help to the patient! subway surfers
By Robert110
Jun 05, 2020 5:32:46 am
Most of them achieved a very good partial response or better, including three patients with stringent complete or complete responses for the nursing essay writers UK.
By oliver010
Jun 06, 2020 4:18:08 am
Belantamab mafodotine, formerly known as GSK2857916, is a cell maturation antibody (BCMA) covalent in patients with recurrent/refractory multiple myeloma nursing essay writing service and other advanced hematologic malignancies expressing BCMA that have developed in stage II clinical development.
By ashu
Jun 06, 2020 5:07:44 am
with the introduction of new technology such as ALTOROTATEPDF there are mix reviews that can encourage people to use it. Organizations such as https://de.altorotatepdf.com/faq provides a platform where people can give reviews. This creates an image of company in the eyes of potential customers
By jacky1100
Jun 08, 2020 5:27:42 am
18 achieved a very good partial response or better, including three patients with stringent complete or complete responses. While the rest of the management assignment writing service are complete with the submissions of there tasks.
By william 552
Jun 09, 2020 5:22:37 am
Reflection of multiple myeloma occurs when cancer does not respond to treatment. coursework help UK in some patients, cancer may respond to first-line treatment, but not heal after a relapse.
By ashu
Jun 12, 2020 9:17:22 am
Wow, this is really interesting reading. I am glad I found this and got to read it. Great job on this content. I like it. ?????
By noah110
Jun 20, 2020 7:23:07 am
Current treatments for refractory tertiary diseases are limited, including conventional chemotherapy, transplantation of autologous stem cells, English essay writers UK, and recycling of previous therapies, which generally have a short-term effect.
By oliver010
Jun 23, 2020 6:09:16 am
The FDA granted priority review to belantamab mandolin for the treatment of patients with best [url=https://royalukessaywriters.co.uk/law-essay-writing-services/]law essay writers[/url] relapsed or refractory multiple myeloma who previously received an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38.
By william 552
Jun 25, 2020 6:30:20 am
The FDA granted priority review to belantamab mandolin for the treatment of patients with relapsed or nursing essay writers UK refractory multiple myeloma who previously received an immunomodulatory agent, a proteasome.
By william 552
Jul 10, 2020 7:56:03 am
The FDA granted priority review to belantamab mandolin for the treatment of patients with relapsed or refractory business dissertation writing multiple myeloma who previously received an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, according to a press release from the drug's manufacturer.
By william 552
Jul 13, 2020 7:15:14 am
The FDA granted a priority review to belantamab mandolin for the treatment of heavily pre-treated patients finance dissertation help with relapsed or refractory multiple myeloma, according to GlaxoSmithKline.
By Treat Assignment Help
Jul 21, 2020 5:26:56 am
Hire Finance Assignment Help experts online at very affordable prices to get good grades. To avail finance assignment writing services in UK order now Quickly.For more services : Data Flow Diagrams Assignment Help | MATLAB Assignment Help | C Programming Assignment Help | Perl Assignment Help | Essay Help UK | Essay Help USA
By william 552
Aug 06, 2020 8:04:48 am
the FDA granted priority review to belantamab mandolin for the treatment of patients with relapsed or refractory multiple myeloma who previously received an immunomodulatory agent, a proteasome inhibitor dissertation writing services and an anti-CD38 antibody, according to a press release from the drug's manufacturer.
By william 552
Aug 13, 2020 7:29:47 am
Priority review is a program of the United States Food and Drug Administration FDA to expedite the review process for drugs essay writer that are expected to have a particularly great impact on the treatment of a disease.
By flavia110
Sep 07, 2020 10:37:51 am
The FDA granted a priority review to belantamab mafodotin for the treatment of heavily custom dissertation help pre-treated patients with relapsed or refractory multiple myeloma, according to GlaxoSmithKline.
By william 552
Sep 15, 2020 5:34:09 am
The FDA granted a priority review to belantamab mafodotin for the treatment of heavily pre-treated patients law essay help UK with relapsed or refractory multiple myeloma, according to GlaxoSmithKline.
Reply
You must log in to use this feature, please click here to login.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.